This podcast was originally published by Dr. Rashmi Murthy on December 11, 2019 on breastcancer.org here.
Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.
Listen to the episode to hear Dr. Murthy explain:
- A summary of the study results
- Why this study included people with brain metastases
- The side effects of tucatinib
- Why she thinks the results are practice changing